Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
40.65 HKD | -1.81% | -7.61% | -12.39% |
Jun. 04 | Akeso Expands Territory of License Agreement for Lung Cancer Drug | MT |
Jun. 03 | Summit Therapeutics Inc. Expands License Territories for Ivonescimab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.39% | 4.51B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- 9926 Stock
- News Akeso, Inc.
- Nomura Adjusts Akeso's Price Target to HK$50.14 From HK$46.04, Keeps at Buy